Gelstat Interest Coverage
The Interest Coverage Ratio of Gelstat (GSAC) as of Jul 23, 2026 is -3.19. In the previous year, Interest Coverage Ratio was -1.36 — a change of 134.62% (lower).
Get this data via API
Financial Data API
Interest Coverage
-3.19
YoY
134.62%
Last updated:
Interest Coverage Ratio of Gelstat is 2026 -3.19 . Interest Coverage Ratio of Gelstat was 2025 -1.36 . It decreases by 134.62% lower compared to the previous year.
Access this data via the Eulerpool API
Gelstat Stock analysis
What does Gelstat do? The Gelstat Corporation is a US-American company specializing in the production of pharmaceuticals and complementary preparations. The development and marketing of products that improve well-being and health is at the center of the company's business model.
The Gelstat Corporation was founded in 2004 by Dr. Thomas Smith and Dr. David Knopman. Originally, the company focused on the development of methods for the diagnosis of degenerative brain diseases. In collaboration with renowned research institutions and universities, the Gelstat Corporation was able to achieve valuable achievements in this field.
In 2008, the company expanded its portfolio and began producing medications and dietary supplements. The Gelstat Corporation focused particularly on the use of ingredients that have positive effects on the body and well-being according to scientific studies.
Currently, the company is divided into two main divisions: Gelstat Migraine and Gelstat Sleep. Gelstat Migraine is an over-the-counter preparation used for pain relief in migraine attacks. The product contains a high concentration of magnesium and therefore does not cause side effects such as nausea or dizziness that can occur with many other pain relievers. The use of Gelstat Migraine in combination with other medications is also safe.
Gelstat Sleep is a dietary supplement taken to improve sleep quality. It contains a combination of plant-based ingredients such as valerian, passionflower, and melatonin. These active ingredients have a calming effect and can help to fall asleep and stay asleep more quickly. Gelstat Sleep is free of chemical substances and therefore suitable for long-term use.
In addition to the two main divisions, Gelstat Corporation also offers other products based on natural ingredients. These include dietary supplements to strengthen the immune system, products for joint discomfort, and for improving memory performance.
The goal of Gelstat Corporation is to promote the health and well-being of people in a natural way. The company ensures that all production steps are carried out under strict quality controls. The product development is also based on scientific studies and done in close collaboration with experts in the respective field.
In summary, the Gelstat Corporation is an innovative company specializing in the production of pharmaceuticals and complementary preparations. The company's products are based on natural ingredients and have positive effects on the well-being and health of people. Through close collaboration with experts and strict adherence to quality standards, Gelstat Corporation has quickly made a name for itself in the industry. Gelstat is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Gelstat stock
Interest Coverage Ratio of Gelstat is -3.19 in 2026.
Access this data via the Eulerpool API
Leverage — Gelstat
All Key Metrics — Gelstat
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth